INTRODUCTION AND OBJECTIVES: Sequential BCG/EMDA-MMC was previously reported to be superior to BCG alone, and since 2009, has been the standard induction regimen in our institution for the treatment of HR-NMIBC. We now present medium-term outcomes from this study.
METHODS: From June 2009 to June 2013, all patients undergoing bladder conservation for HR-NMIBC were offered sequential BCG/EMDA-MMC. BCG (Immucyst until June 2012, Oncotice since Sept 2012) was given in weeks 1 and 2, and EMDA-MMC (40mg, intravesical current 20mA for 30 mins) in week 3, and this cycle was repeated 3 times for a total of 9 weeks. Maintenance treatment was with 3 doses of BCG every 6 months, commencing 3 months after induction. Response was assessed by GA cystoscopy 8 weeks post induction, followed by 6-monthly flexible cystoscopy.
RESULTS: 151 patients with HR-NMIBC were treated, of whom 44 (29%) received primary cystectomy, leaving 107 patients (71%) treated with sequential BCG/EMDA-MMC. 86/107 (80%) had high grade Ta/T1 disease, of whom 34 (32%) also had carcinoma in situ (CIS). 19/107 (18%) had primary CIS. 2 (2%) had recurrent, large volume, low grade disease. Median length of follow-up was 47 months (range 4-87 months). 1 patient was lost to follow-up immediately after induction and was excluded from analysis. Overall, 37/106 (35%) patients had disease recurrence. 7/106 (7%) had disease progression, of whom 2/106 (2%) progressed to higher stage NMIBC, 3/106 (3%) progressed to muscle invasive bladder cancer (MIBC), and 2/106 (2%) developed distant metastases. 11/106 (10%) eventually underwent cystectomy for the following reasons: progression to MIBC (3/11), disease recurrence (7/11) and severe bladder storage symptoms (1/11). 17/106 patients (16%) have died, of which 2/106 (2%) died from bladder cancer. As previously reported, 30/107 patients were unable to complete the full 9-dose induction schedule, 16/30 directly due to side effects. There was no significant difference in recurrence rates between patients who received a full (36%) versus a reduced (30%) induction schedule (X2¼0.39, p¼0.53).
CONCLUSIONS: Despite the challenge of a 4-year recurrence rate of 35%, a low progression rate to muscle-invasive and metastatic disease of 5% and disease-specific mortality of 2% continue to attest to the oncological efficacy of sequential BCG/EMDA-MMC.
Source of Funding: None

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY
TR Leyshon Griffiths*, William JF Green, Peter T Grice, Jonathan C Goddard, Roger C Kockelbergh, Leicester, United Kingdom INTRODUCTION AND OBJECTIVES: Until October 2014, our standard bladder-sparing treatment for high risk (HR) non-muscle invasive bladder cancer (NMIBC) was a full-dose intravesical bacillus Calmette-Guerin (BCG) 6-week induction course and maintenance BCG for 1-3 years. In response to the BCG shortage, we modified our regimen to sequential full-dose BCG and deviceassisted chemo-hyperthermia (Mitomycin C [MMC] delivered by the Combat BRS system). Here we present our 1-year results after start of treatment.
METHODS: The 6-week induction regimen became BCG (weeks 1,2), Combat BRS (weeks 3,4,5) and BCG (week 6). Nine further Combat BRS maintenance treatments were given by 1 year comprising 3 sets of weekly instillations for 3 weeks. We reviewed the 1-year follow-up results of 50 HR-NMIBC (high grade [grade 3] and/or carcinoma in situ [CIS] ) patients who commenced treatment between October 2014 and September 2015. T1 tumours represented 62% of cases and were routinely re-resected. CIS was detected in 40% of cases. We excluded 11 patients from this series who had concurrent upper urinary tract or prostatic urothelial tumours, previous radiotherapy or BCG or a course of MMC.
RESULTS: Of 50 patients, 44 (88%) were disease-free by 1 year; 3 (6%) had refractory HR-NMIBC at 6 months, 2 (4%) progressed to MIBC by 6 months and 1 (2%) presented with metastatic disease at 1 year. All 6 had CIS and/or T1 at diagnosis. Forty-three patients (86%) tolerated Combat BRS treatment; 2 reacted with rashes during maintenance and 5 had bladder-related tolerability issues.
CONCLUSIONS: Our oncological results with sequential BCG/ Combat BRS at 1 year are at least comparative at this time-point with those expected for HR-NMIBC patients on maintenance BCG. Tolerability and compliance shows great promise.
Source of Funding: None
PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL
INTRODUCTION AND OBJECTIVES: Despite maintenance BCG, 50% of patients will develop bladder cancer recurrence and 10-20% will progress within 52 months. There is no effective second-line therapy for NMIBC following BCG failure. The combination of intravesical mitomycin-C (MMC) with RITE has shown efficacy when compared to BCG. This study aims to determine whether RITE improves disease-free survival (DFS) compared to standard of care in patients with recurrence of NMIBC following BCG.
METHODS: This multicentre, open-label, phase III randomised controlled trial was performed in 14 UK centres (ClinicalTrials.gov: NCT01094964). Patients with NMIBC who developed recurrence following BCG induction/maintenance therapy were randomly assigned (1:1) to either RITE (60 min, 40 mg mitomycin-C at 42 C) using the Synergoâ SB-TS 101 System or a second course of BCG/ institutional standard. All patients had complete resection of papillary visible tumours and must be either unfit or unwilling to have radical cystectomy. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e367
